Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients

被引：8

作者：

Reinhard, H. ^{[1
,2
]}

Yousef, S. ^{[1
,2
,3
,4
]}

Luetkens, T. ^{[1
,2
,3
]}

Fehse, B. ^{[4
]}

Berdien, B. ^{[4
]}

Kroeger, N. ^{[4
]}

Atanackovic, D. ^{[1
,2
,3
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 2, Hamburg, Germany

[2] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Hamburg, Germany

[3] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[4] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

来源：

BLOOD CANCER JOURNAL | 2014年 / 4卷

关键词：

MAGE FAMILY; LYMPHOCYTES; MAGE-C1/CT7; EXPRESSION;

D O I：

10.1038/bcj.2014.31

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：e212 / e212

页数：3

共 17 条

[1] Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation [J].

Atanackovic, Djordje ;

Arfsten, Julia ;

Cao, Yanran ;

Gnjatic, Sacha ;

Schnieders, Frank ;

Bartels, Katrin ;

Schilling, Georgia ;

Faltz, Christiane ;

Wolschke, Christine ;

Dierlamm, Judith ;

Ritter, Gerd ;

Eiermann, Thomas ;

Hossfeld, Dieter Kurt ;

Zander, Axel R. ;

Jungbluth, Achim A. ;

Old, Lloyd J. ;

Bokemeyer, Carsten ;

Kroeger, Nicolaus .

BLOOD, 2007, 109 (03) :1103-1112

[2] MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair [J].

Bhatia, Neehar ;

Xiao, Tony Z. ;

Rosenthal, Kimberly A. ;

Siddiqui, Imtiaz A. ;

Thiyagarajan, Saravanan ;

Smart, Brendan ;

Meng, Qiao ;

Zuleger, Cindy L. ;

Mukhtar, Hasan ;

Kenney, Shannon C. ;

Albertini, Mark R. ;

Longley, B. Jack .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (03) :759-767

[3] Multiple myeloma [J].

Blade, J. ;

Teresa Cibeira, M. ;

Fernandez de Larrea, C. ;

Rosinol, L. .

ANNALS OF ONCOLOGY, 2010, 21 :313-319

[4] MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy [J].

de Carvalho, Fabricio ;

Alves, Veruska L. F. ;

Braga, Walter M. T. ;

Xavier, Celso V., Jr. ;

Colleoni, Gisele W. B. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (01) :191-195

[5] T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells [J].

Dhodapkar, MV ;

Krasovsky, J ;

Olson, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) :13009-13013

[6]

Güre AO, 2000, INT J CANCER, V85, P726, DOI 10.1002/(SICI)1097-0215(20000301)85:5<726::AID-IJC21>3.0.CO

[7]

2-F

[8] Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes [J].

Hayashi, T ;

Hideshima, T ;

Akiyama, M ;

Rajo, N ;

Richardson, P ;

Chauhan, D ;

Anderson, KC .

BLOOD, 2003, 102 (04) :1435-1442

[9] The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma [J].

Lokhorst, HM ;

Wu, KL ;

Verdonck, LF ;

Laterveer, LL ;

Van de Donk, NWCJ ;

van Oers, MHJ ;

Cornelissen, JJ ;

Schattenberg, AV .

BLOOD, 2004, 103 (11) :4362-4364

[10]

Lucas S, 2000, INT J CANCER, V87, P55, DOI 10.1002/1097-0215(20000701)87:1<55::AID-IJC8>3.0.CO

← 1 2 →